HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Protagonist Therapeutics (NASDAQ:PTGX) and maintained a $38 price target.
May 09, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Protagonist Therapeutics with a $38 price target.
The reiteration of a Buy rating and maintenance of a $38 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence among investors and potentially lead to a positive short-term impact on PTGX's stock price. Analyst ratings, especially from well-regarded firms, often influence investor perception and can lead to stock price movements.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100